Ignite Creation Date:
2024-10-25 @ 7:57 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06635993
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-09
Brief Title:
Accuracy of 68Ga-Pentixafor PETCT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Accuracy of 68Ga-Pentixafor PETCT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ABOARD
Brief Summary:
To evaluate the accuracy of 68Ga-Pentixafor PET-CT in the classification diagnosis of primary aldosteronism concurrent with autonomous cortisol secretion patient using AVS andor postoperative remission as the reference standard for classification diagnosis
Detailed Description:
This study is a multicenter prospective diagnostic trial involving patients with primary aldosteronism PA concurrent with autonomous cortisol secretion ACS patients with adrenal nodule 1cm who completed both AVS and 68Ga-Pentixafor PETCT We will enroll 97 PA concurrent with ACS patients with adrenal nodule 1cm The treatment plan was determined according to the AVS results AVS andor postoperative remission were used as the reference standard for classification diagnosis to evaluate the accuracy of 68Ga-Pentixafor PET-CT in the classification diagnosis of PA concurrent with ACS patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None